DR. ANISHA R

DR. SUBRAMANYA KOTA, DR. GURU PRASAD N S, DR. ANUSHA GOUDAR

Abstract

Purpose: To determine the prevalence of different stages of COVID associated mucormycosis.

Method: A Tertiary care Hospital based study involving 363 patients with COVID associated mucormycosis who underwent clinical staging from May 2021 to August 2021.

Results: Out of 363 patients with mucormycosis, 75% were males and 25% were females. Clinical staging of these COVID associated mucormycosis cases showed that 1% were stage 1, 40% were stage 2, 48% were stage 3, and 11% were under stage 4. Sub grouping under the said stages revealed that stage 3B was most prevalent followed by stage 2A and stage 3C.

Conclusion: In the current study, lack of awareness among patients to detect early symptoms and signs of COVID associated mucormycosis may be the reason for increase in prevalence of advanced stages than the initial stages. Aggressive nature of pathogenic organism causing the infection may also be stated as one of the reasons for presentation of patients in fully advanced stages.